1. A risk model to identify Legionella among patients admitted with community-acquired pneumonia: a retrospective cohort study;Rothberg;J Hosp Med,2022
2. Risk factors for sporadic community-acquired Legionnaires' disease. A 3-year national case-control study;Den Boer;Public Health,2006
3. Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists;Tubach;Clin Infect Dis,2006
4. Infectious complications associated with immunomodulating biologic agents;Koo;Infect Dis Clin North Am,2010
5. U.S. Food and Drug Administration (FDA). FDA Drug Safety Communication: Drug labels for the tumor necrosis factor-alpha (TNFα) blockers now include warnings about infection with Legionella and Listeria bacteria. Available at:https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-drug-labels-tumor-necrosis-factor-alpha-tnfa-blockers-now-include. Accessed November 28, 2023.